{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:04:46Z","timestamp":1790798686199,"version":"4.1.0"},"reference-count":312,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Alzheimer\u2019s Disease (AD) is a progressive neurodegenerative disease for which disease-modifying therapies remain limited. Despite extensive efforts targeting amyloid-\u03b2 and tau, these approaches have not translated into clear clinical benefit, underscoring the need for a more integrated understanding of AD pathogenesis. This narrative review summarizes recent advances in the molecular mechanisms underlying AD and evaluates current and emerging therapeutic strategies. A literature search was conducted using PubMed, Google Scholar, Web of Science and Scopus, focusing on preclinical and clinical studies addressing AD pathophysiology and treatment development. Conclusion: We summarize key pathogenic pathways, including A\u03b2 aggregation, tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, and metabolic dysregulation, and discuss how these interconnected processes have informed drug development efforts. Particular attention is given to limitations of single-target approaches and the growing interest in multi-target and combination therapies. In conclusion, a better understanding of the pathological mechanisms underlying AD may contribute to the development of more effective pharmacological therapies and integrated therapeutic approaches targeting the multifactorial nature of the disease.<\/jats:p>","DOI":"10.3389\/fphar.2026.1819165","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:57:37Z","timestamp":1781675857000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in the treatment of Alzheimer\u2019s disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Rezzan","family":"Temelli Goceroglu","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Van Yuzuncu Yil University","place":["Van, T\u00fcrkiye"]},{"name":"Department of Medical Pharmacology, Faculty of Medicine, Atat\u00fcrk University","place":["Erzurum, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Hacimuftuoglu","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmacology, Faculty of Medicine, Atat\u00fcrk University","place":["Erzurum, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.21608\/jmals.2021.210630","article-title":"Celecoxib effect on rivastigmine anti-alzheimer activity against aluminum chloride-induced neurobehavioral deficits as a rat model of alzheimer's disease; novel perspectives for an old drug","author":"Aal","year":"2021","journal-title":"J. Med. Life Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"117996","DOI":"10.1016\/j.lfs.2020.117996","article-title":"Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions","volume":"256","author":"Abeysinghe","year":"2020","journal-title":"Life Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.14283\/jpad.2017.26","article-title":"Clinical effects of tramiprosate in APOE4\/4 homozygous patients with mild alzheimer's disease suggest disease modification potential","volume":"4","author":"Abushakra","year":"2017","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e12498","DOI":"10.1002\/trc2.12498","article-title":"APOLLOE4 phase 3 study of oral ALZ-801\/valiltramiprosate in APOE \u03b54\/\u03b54 homozygotes with early alzheimer's disease: trial design and baseline characteristics","volume":"10","author":"Abushakra","year":"2024","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.biopha.2018.06.147","article-title":"A molecular approach in drug development for alzheimer's disease","volume":"106","author":"Agatonovic-Kustrin","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1007\/s12035-021-02350-9","article-title":"Verapamil prevents development of cognitive impairment in an aged mouse model of sporadic alzheimer's disease","volume":"58","author":"Ahmed","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2165\/00023210-200519120-00002","article-title":"The development of anti-amyloid therapy for alzheimer's disease: from secretase modulators to polymerisation inhibitors","volume":"19","author":"Aisen","year":"2005","journal-title":"CNS Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13195-017-0283-5","article-title":"On the path to 2025: understanding the alzheimer's disease continuum","volume":"9","author":"Aisen","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"705575","DOI":"10.3389\/fphys.2021.705575","article-title":"Sigmar1\u2019s molecular, cellular, and biological functions in regulating cellular pathophysiology","volume":"12","author":"Aishwarya","year":"2021","journal-title":"Front. Physiology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.7324\/JAPS.2022.121013","article-title":"Assessment of the genotoxicity and cytotoxicity of etazolate in cultured human lymphocytes","volume":"12","author":"Al","year":"2022","journal-title":"J. Appl. Pharm. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3233\/JAD-150277","article-title":"Selective brain-targeted antagonism of p38 MAPK\u03b2 reduces hippocampal IL-1\u03b2 levels and improves morris water maze performance in aged rats","volume":"48","author":"Alam","year":"2015","journal-title":"J. Alzheimer's Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1708","DOI":"10.1212\/wnl.0000000000207755","article-title":"Association of plasma phosphorylated tau with the response to neflamapimod treatment in patients with dementia with lewy bodies","volume":"101","author":"Alam","year":"2023","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11011-021-00888-0","article-title":"Beneficial effects of levetiracetam in streptozotocin-induced rat model of alzheimer's disease","volume":"37","author":"Alavi","year":"2022","journal-title":"Metab. Brain Dis."},{"key":"B14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/B978-0-12-803959-5.50008-8","article-title":"Chapter 8 - research strategies developed for the treatment of alzheimer\u2019s disease. Reversible and pseudo-irreversible inhibitors of acetylcholinesterase: structure-activity relationships and drug design","volume-title":"Drug Design and Discovery in Alzheimer's disease","author":"Alcolea-Palafox","year":"2014"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jsps.2022.10.004","article-title":"An update on the novel and approved drugs for alzheimer disease","volume":"30","author":"Alhazmi","year":"2022","journal-title":"Saudi Pharm. J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3233\/jad-231163","article-title":"Alzheimer's disease immunotherapy: current strategies and future prospects","volume":"98","author":"Aljassabi","year":"2024","journal-title":"J. Alzheimers Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1021\/acschemneuro.0c00096","article-title":"Physiological and pathological roles of Cdk5: potential directions for therapeutic targeting in neurodegenerative disease","volume":"11","author":"Allnutt","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.3390\/life13081688","article-title":"Repurposing diltiazem for its neuroprotective anti-dementia role against intra-cerebroventricular streptozotocin-induced sporadic alzheimer's disease-type rat model","volume":"13","author":"Alluri","year":"2023","journal-title":"Life (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aal2021","article-title":"The amyloid-\u03b2 oligomer A\u03b2*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation","volume":"10","author":"Amar","year":"2017","journal-title":"Sci. Signal"},{"key":"B20","doi-asserted-by":"publisher","first-page":"115522","DOI":"10.1016\/j.bcp.2023.115522","article-title":"Alzheimer\u2019s disease: insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs","volume":"211","author":"Ana","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/jnc.15900","article-title":"Obesity during preclinical alzheimer's disease development exacerbates brain metabolic decline","volume":"168","author":"Anderson","year":"2024","journal-title":"J. Neurochem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0098153","DOI":"10.1371\/journal.pone.0098153","article-title":"First administration of the Fc-attenuated anti-\u03b2 amyloid antibody GSK933776 to patients with mild alzheimer's disease: a randomized, placebo-controlled study","volume":"10","author":"Andreasen","year":"2015","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"104511","DOI":"10.1016\/j.ebiom.2023.104511","article-title":"The complex genetic architecture of alzheimer's disease: novel insights and future directions","volume":"90","author":"Andrews","year":"2023","journal-title":"EBioMedicine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100163","DOI":"10.1016\/j.tjpad.2025.100163","article-title":"Challenges and opportunities for novel combination therapies in alzheimer's disease: a report from the EU\/US CTAD task force","volume":"12","author":"Angioni","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"640","DOI":"10.4103\/aian.aian_748_25","article-title":"Disease-modifying drugs for alzheimer's disease: bending the curve","volume":"28","author":"Arshad","year":"2025","journal-title":"Ann. Indian Acad. Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1515\/cclm-2023-1434","article-title":"Blood-based biomarkers in alzheimer's disease - moving towards a new era of diagnostics","volume":"62","author":"Arslan","year":"2024","journal-title":"Clin. Chem. Lab. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1007\/s11033-021-06512-9","article-title":"Recent advances on drug development and emerging therapeutic agents for Alzheimer\u2019s disease","volume":"48","author":"Athar","year":"2021","journal-title":"Mol. Biology Reports"},{"key":"B28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0039-1678581","article-title":"Current and future treatments in alzheimer's disease","volume":"39","author":"Atri","year":"2019","journal-title":"Semin. Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2017.20373","article-title":"Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with alzheimer disease: three randomized clinical trials","volume":"319","author":"Atri","year":"2018","journal-title":"Jama"},{"key":"B30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-025-01921-5","article-title":"Clinical translation of fluid, imaging, and digital biomarkers for alzheimer's disease","volume":"18","author":"Bacci","year":"2026","journal-title":"Alzheimers Res. and Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"7729","DOI":"10.1002\/alz.14233","article-title":"Hypertension and cerebral blood flow in the development of alzheimer's disease","volume":"20","author":"Bachmann","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B32","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited alzheimer's disease","volume":"26","author":"Barth\u00e9lemy","year":"2020","journal-title":"Nat. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.conb.2019.11.024","article-title":"Genetics of Alzheimer\u2019s disease: where we are, and where we are going","volume":"61","author":"Bellenguez","year":"2020","journal-title":"Curr. Opin. Neurobiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","article-title":"New insights into the genetic etiology of alzheimer's disease and related dementias","volume":"54","author":"Bellenguez","year":"2022","journal-title":"Nat. Genet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.tips.2020.04.008","article-title":"A perspective on multi-target drugs for Alzheimer\u2019s disease","volume":"41","author":"Benek","year":"2020","journal-title":"Trends Pharmacological Sciences"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2052142","DOI":"10.1155\/2024\/2052142","article-title":"Advancements and challenges in antiamyloid therapy for alzheimer\u2019s disease: a comprehensive review","volume":"2024","author":"Beshir","year":"2024","journal-title":"Int. J. Alzheimer\u2019s Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"104707","DOI":"10.1016\/j.nbd.2019.104707","article-title":"Advances and considerations in AD tau-targeted immunotherapy","volume":"134","author":"Bittar","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early alzheimer's disease","volume":"9","author":"Budd","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jalz.2016.01.012","article-title":"Molecular genetics of early-onset alzheimer's disease revisited","volume":"12","author":"Cacace","year":"2016","journal-title":"Alzheimer's and Dementia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12017-011-8155-9","article-title":"Oxidative stress and \u03b2-Amyloid protein in alzheimer\u2019s disease","volume":"13","author":"Cai","year":"2011","journal-title":"NeuroMolecular Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1176\/appi.ajp.2021.20091339","article-title":"Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial","volume":"178","author":"Calabrese","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"795375","DOI":"10.1155\/2014\/795375","article-title":"Amyloid beta: multiple mechanisms of toxicity and only some protective effects?","volume":"2014","author":"Carrillo-Mora","year":"2014","journal-title":"Oxid. Med. Cell. Longev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.redox.2017.10.014","article-title":"Oxidative stress and the amyloid beta peptide in alzheimer's disease","volume":"14","author":"Cheignon","year":"2018","journal-title":"Redox Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12974-023-02853-3","article-title":"Tau and neuroinflammation in alzheimer's disease: interplay mechanisms and clinical translation","volume":"20","author":"Chen","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"B46","doi-asserted-by":"publisher","first-page":"881239","DOI":"10.3389\/fnagi.2022.881239","article-title":"A review of ApoE4 interference targeting mitophagy molecular pathways for alzheimer's disease","volume":"14","author":"Chen","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ca.23727","article-title":"Trace element alterations in alzheimer's disease: a review","volume":"34","author":"Cilliers","year":"2021","journal-title":"Clin. Anat."},{"key":"B48","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.freeradbiomed.2009.12.022","article-title":"Reactive oxygen species, cellular redox systems, and apoptosis","volume":"48","author":"Circu","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ijge.2016.07.003","article-title":"New therapeutic targets in alzheimer's disease","volume":"11","author":"Coman","year":"2017","journal-title":"Int. Journal Gerontology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for alzheimer disease: current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jocn.2010.04.020","article-title":"Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an alzheimer's disease model","volume":"17","author":"Corcoran","year":"2010","journal-title":"J. Clin. Neurosci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1016\/j.cell.2025.11.033","article-title":"The evolving landscape of Alzheimer\u2019s disease therapy: from A\u03b2 to tau","volume":"188","author":"Courade","year":"2025","journal-title":"Cell."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e1889","DOI":"10.1212\/wnl.0000000000005550","article-title":"ABBY: a phase 2 randomized trial of crenezumab in mild to moderate alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e12465","DOI":"10.1002\/trc2.12465","article-title":"Alzheimer's disease drug development pipeline: 2024","volume":"10","author":"Cummings J.","year":"2024","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40263-024-01103-1","article-title":"Alzheimer\u2019s disease: combination therapies and clinical trials for combination therapy development","volume":"38","author":"Cummings","year":"2024","journal-title":"CNS Drugs"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e70098","DOI":"10.1002\/trc2.70098","article-title":"Alzheimer's disease drug development pipeline: 2025","volume":"11","author":"Cummings","year":"","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B58","doi-asserted-by":"publisher","first-page":"100328","DOI":"10.1016\/j.tjpad.2025.100328","article-title":"Alzheimer combination therapies: overview and scenarios","volume":"12","author":"Cummings","year":"","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"102713","DOI":"10.1016\/j.arr.2025.102713","article-title":"Mitochondrial dysfunction in alzheimer's disease","volume":"107","author":"D'Alessandro","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115911","article-title":"When good kinases Go rogue: GSK3, p38 MAPK and CDKs as therapeutic targets for alzheimer's and huntington's disease","volume":"22","author":"D'Mello","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2174\/0118715273376581250626003322","article-title":"Tau pathology in alzheimer's disease: bridging molecular mechanisms and targeted therapies","volume":"24","author":"Dahiya","year":"2025","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1007\/s00018-019-03132-2","article-title":"Microglial priming of antigen presentation and adaptive stimulation in alzheimer's disease","volume":"76","author":"Das","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40263-019-00613-7","article-title":"A close look at BACE1 inhibitors for alzheimer's disease treatment","volume":"33","author":"Das","year":"2019","journal-title":"CNS Drugs"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s11011-021-00765-w","article-title":"Role of metals in alzheimer's disease","volume":"36","author":"Das","year":"2021","journal-title":"Metab. Brain Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3233\/adr-220108","article-title":"Common signaling pathways involved in alzheimer's disease and stroke: two faces of the same coin","volume":"7","author":"Das","year":"2023","journal-title":"J. Alzheimers Dis. Rep."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2147\/dddt.S86463","article-title":"A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe alzheimer's disease","volume":"10","author":"Deardorff","year":"2016","journal-title":"Drug Des. Devel Ther."},{"key":"B67","doi-asserted-by":"publisher","first-page":"207178","DOI":"10.1155\/2013\/207178","article-title":"Alzheimer's disease clinical and research update for health care practitioners","volume":"2013","author":"DeFina","year":"2013","journal-title":"J. Aging Research"},{"key":"B68","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3233\/JAD-2012-120805","article-title":"Treatment of alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study","volume":"33","author":"Del Ser","year":"2013","journal-title":"J. Alzheimer's Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2147\/ndt.S106479","article-title":"A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts","volume":"12","author":"Dell'Osso","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B70","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.3390\/molecules29184354","article-title":"p38\u03b1 mitogen-activated protein Kinase-An emerging drug target for the treatment of alzheimer's disease","volume":"29","author":"Detka","year":"2024","journal-title":"Molecules"},{"key":"B71","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1002\/alz.13882","article-title":"Diabetes accelerates alzheimer's disease progression in the first year post mild cognitive impairment diagnosis","volume":"20","author":"Ding","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B72","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1074\/jbc.M111.306472","article-title":"Evidence for irreversible inhibition of glycogen synthase kinase-3\u03b2 by tideglusib","volume":"287","author":"Dom\u00ednguez","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B73","doi-asserted-by":"publisher","first-page":"177644","DOI":"10.1016\/j.ejphar.2025.177644","article-title":"Antisense oligonucleotides: a promising advancement in neurodegenerative disease treatment","volume":"999","author":"Dudzisz","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/ijnp\/pyaa078","article-title":"Alogliptin attenuates lipopolysaccharide-induced neuroinflammation in mice through modulation of TLR4\/MYD88\/NF-\u03baB and miRNA-155\/SOCS-1 signaling pathways","volume":"24","author":"El-Sahar","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1212\/WNL.0000000000001017","article-title":"Increased CSF APPs-\u03b1 levels in patients with alzheimer disease treated with acitretin","volume":"83","author":"Endres","year":"2014","journal-title":"Neurology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1001\/jamaneurol.2024.3533","article-title":"Digital biomarkers for neurodegenerative disease","volume":"82","author":"Erickson","year":"2025","journal-title":"JAMA Neurol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.3233\/jad-231126","article-title":"Varoglutamstat: inhibiting glutaminyl cyclase as a novel target of therapy in early alzheimer\u2019s disease","volume":"101","author":"Feldman","year":"2024","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s43556-026-00443-2","article-title":"Alzheimer's disease: from molecular pathways to therapies","volume":"7","author":"Feng","year":"2026","journal-title":"Mol. Biomed."},{"key":"B79","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3389\/fnagi.2018.00226","article-title":"Effect of cholesterol on membrane fluidity and association of A\u03b2 oligomers and subsequent neuronal damage: a double-edged sword","volume":"10","author":"Fern\u00e1ndez-P\u00e9rez","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"B80","doi-asserted-by":"publisher","first-page":"113492","DOI":"10.1016\/j.ejmech.2021.113492","article-title":"Dual-target compounds for alzheimer's disease: natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR)","volume":"221","author":"Ferreira","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B81","doi-asserted-by":"publisher","first-page":"100327","DOI":"10.1016\/j.tjpad.2025.100327","article-title":"Harnessing combination therapy: current treatments, recent advancements, and future directions in alzheimer's disease","volume":"12","author":"Fillit","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/brain\/awad024","article-title":"Tilavonemab in early alzheimer's disease: results from a phase 2, randomized, double-blind study","volume":"146","author":"Florian","year":"2023","journal-title":"Brain"},{"key":"B83","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1192\/bjp.bp.110.080044","article-title":"Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial","volume":"198","author":"Forlenza","year":"2011","journal-title":"Br. J. Psychiatry"},{"key":"B84","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-021-00233-1","article-title":"Targeting oxidative stress in disease: promise and limitations of antioxidant therapy","volume":"20","author":"Forman","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B85","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/antiox10020218","article-title":"Implication of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and its inhibitors in alzheimer's disease murine models","volume":"10","author":"Fragoso-Morales","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.14283\/jpad.2024.163","article-title":"Phase 1 studies of the anti-tau monoclonal antibody JNJ-63733657 in healthy participants and participants with alzheimer's disease","volume":"11","author":"Galpern","year":"2024","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2147\/dddt.S130514","article-title":"Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in alzheimer's disease and parkinson's disease","volume":"11","author":"Ganguly","year":"2017","journal-title":"Drug Des. Devel Ther."},{"key":"B88","doi-asserted-by":"publisher","first-page":"7086512","DOI":"10.1155\/2021\/7086512","article-title":"Oxidative stress, neuroinflammation, and NADPH oxidase: implications in the pathogenesis and treatment of alzheimer's disease","volume":"2021","author":"Ganguly","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"B89","doi-asserted-by":"publisher","first-page":"176760","DOI":"10.1016\/j.ejphar.2024.176760","article-title":"CDK5 as a therapeutic tool for the treatment of alzheimer's disease: a review","volume":"978","author":"Garemilla","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"B91","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","article-title":"Targeting soluble A\u03b2 peptide with tramiprosate for the treatment of brain amyloidosis","volume":"28","author":"Gervais","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"B92","doi-asserted-by":"publisher","first-page":"36","DOI":"10.37349\/ent.2022.00017","article-title":"Various facets of excitotoxicity","volume":"2","author":"Glaser","year":"2022","journal-title":"Explor. Neuroprotective Ther."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1038\/s41591-023-02543-w","article-title":"Senolytic therapy in mild alzheimer's disease: a phase 1 feasibility trial","volume":"29","author":"Gonzales","year":"2023","journal-title":"Nat. Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fnmol.2018.00151","article-title":"ADNP, a microtubule interacting protein, provides neuroprotection through end binding proteins and tau: an amplifier effect","volume":"11","author":"Gozes","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/ana.26351","article-title":"APOE antibody inhibits A\u03b2\u2010associated tau seeding and spreading in a mouse model","volume":"91","author":"Gratuze","year":"2022","journal-title":"Ann. Neurology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.trci.2018.11.001","article-title":"A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for alzheimer's disease","volume":"5","author":"Grundman","year":"2019","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B97","doi-asserted-by":"publisher","first-page":"102192","DOI":"10.1016\/j.arr.2024.102192","article-title":"Passive immunotherapy for alzheimer's disease","volume":"94","author":"Guo","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"B98","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2174\/0115680266259174231006070637","article-title":"Gamma secretase as an important drug target for management of alzheimer's disease: a comprehensive review","volume":"24","author":"Hakem","year":"2024","journal-title":"Curr. Top. Med. Chem."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/brain\/aww017","article-title":"Early and protective microglial activation in alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging","volume":"139","author":"Hamelin","year":"2016","journal-title":"Brain"},{"key":"B100","doi-asserted-by":"publisher","first-page":"922","DOI":"10.4088\/JCP.08m04606","article-title":"Lithium trial in alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study","volume":"70","author":"Hampel","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"B101","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/jad-190197","article-title":"Lithium as a treatment for alzheimer's disease: the systems pharmacology perspective","volume":"69","author":"Hampel","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"B102","doi-asserted-by":"publisher","first-page":"e12013","DOI":"10.1002\/trc2.12013","article-title":"A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an alzheimer's disease therapy: analysis of the blarcamesine (ANAVEX2-73) phase 2a clinical study","volume":"6","author":"Hampel","year":"2020","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B103","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The \u03b2-Secretase BACE1 in alzheimer's disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biol. Psychiatry"},{"key":"B104","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for alzheimer's disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat. Aging"},{"key":"B105","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","article-title":"Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of alzheimer's disease","volume":"57","author":"Hey","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"B106","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40262-025-01482-8","article-title":"Clinical pharmacokinetics of oral ALZ-801\/Valiltramiprosate in a 2-Year phase 2 trial of APOE4 carriers with early alzheimer's disease","volume":"64","author":"Hey","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"B107","doi-asserted-by":"publisher","first-page":"102348","DOI":"10.1016\/j.arr.2024.102348","article-title":"Donanemab, another anti-alzheimer's drug with risk and uncertain benefit","volume":"99","author":"H\u00f8ilund-Carlsen","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"B108","doi-asserted-by":"publisher","first-page":"77sr1","DOI":"10.1126\/scitranslmed.3002369","article-title":"Alzheimer's disease: the challenge of the second century","volume":"3","author":"Holtzman","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/biom15060824","article-title":"The role and pathogenesis of tau protein in alzheimer's disease","volume":"15","author":"Hong","year":"2025","journal-title":"Biomolecules"},{"key":"B110","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"111069","DOI":"10.1016\/j.pnpbp.2024.111069","article-title":"Alzheimer's disease approaches - focusing on pathology, biomarkers and clinical trial candidates","volume":"134","author":"Hroudov\u00e1","year":"2024","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry"},{"key":"B112","doi-asserted-by":"publisher","first-page":"130618","DOI":"10.1016\/j.molstruc.2021.130618","article-title":"Coumarin linked heterocyclic hybrids: a promising approach to develop multi target drugs for alzheimer's disease","volume":"1241","author":"Husain","year":"2021","journal-title":"J. Mol. Struct."},{"key":"B113","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1515\/revneuro-2024-0007","article-title":"Methylene blue and its potential in the treatment of traumatic brain injury, brain ischemia, and Alzheimer\u2019s disease","volume":"35","author":"Isaev","year":"2024","journal-title":"Rev. Neurosci."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3390\/antiox8030072","article-title":"Measurement and clinical significance of lipid peroxidation as a biomarker of oxidative stress: oxidative stress in diabetes, atherosclerosis, and chronic inflammation","volume":"8","author":"Ito","year":"2019","journal-title":"Antioxidants (Basel)"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/mp.2016.255","article-title":"ADNP\/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy","volume":"22","author":"Ivashko-Pachima","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/alz.12302","article-title":"Preclinical and clinical biomarker studies of CT1812: a novel approach to alzheimer's disease modification","volume":"17","author":"Izzo","year":"2021","journal-title":"Alzheimers Dement."},{"key":"B117","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer's and Dementia"},{"key":"B118","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.2174\/0929867324666170529122802","article-title":"Multi-target-directed ligands affecting serotonergic neurotransmission for alzheimer's disease therapy: advances in chemical and biological research","volume":"25","author":"Jankowska","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"B119","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fncel.2018.00314","article-title":"Sigma-1 receptor-modulated neuroinflammation in neurological diseases","volume":"12","author":"Jia","year":"2018","journal-title":"Front. Cellular Neuroscience"},{"key":"B120","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.1038\/s41467-022-32944-3","article-title":"Preclinical and randomized clinical evaluation of the p38\u03b1 kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat. Commun."},{"key":"B121","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1021\/acschemneuro.3c00266","article-title":"Computationally designed small molecules disassemble both soluble oligomers and protofibrils of amyloid \u03b2-Protein responsible for alzheimer's disease","volume":"14","author":"Jin","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"B122","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jconrel.2024.09.012","article-title":"Amyloid-\u03b2-targeting immunotherapies for alzheimer's disease","volume":"375","author":"Jin","year":"2024","journal-title":"J. Control Release"},{"key":"B123","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11243-012-9583-6","article-title":"Redox active metal-induced oxidative stress in biological systems","volume":"37","author":"Jomova","year":"2012","journal-title":"Transit. Metal. Chem."},{"key":"B124","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10787-024-01608-7","article-title":"Drugs repurposing in the experimental models of alzheimer's disease","volume":"33","author":"Joodi","year":"2025","journal-title":"Inflammopharmacology"},{"key":"B125","doi-asserted-by":"publisher","first-page":"101664","DOI":"10.1016\/j.pneurobio.2019.101664","article-title":"microRNA dysregulation in neurodegenerative diseases: a systematic review","volume":"182","author":"Ju\u017awik","year":"2019","journal-title":"Prog. Neurobiology"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093272","article-title":"Combination drug therapy for the management of alzheimer's disease","volume":"21","author":"Kabir","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B127","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40142-018-0155-8","article-title":"A brief synopsis on the genetics of alzheimer's disease","volume":"6","author":"Kamboh","year":"2018","journal-title":"Curr. Genet. Med. Rep."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s40265-024-02087-4","article-title":"Donanemab: first approval","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs"},{"key":"B129","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.semcdb.2020.12.011","article-title":"Role of notch signaling in neurovascular aging and alzheimer's disease","volume":"116","author":"Kapoor","year":"2021","journal-title":"Semin. Cell. Dev. Biol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/s1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/1028415x.2018.1500124","article-title":"The green tea polyphenolic catechin epigallocatechin gallate and neuroprotection","volume":"23","author":"Khalatbary","year":"2020","journal-title":"Nutr. Neurosci."},{"key":"B132","doi-asserted-by":"publisher","first-page":"12299","DOI":"10.3390\/ijms252212299","article-title":"Molecular roles of NADPH oxidase-mediated oxidative stress in alzheimer's disease: isoform-specific contributions","volume":"25","author":"Kim","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B133","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/2211-5463.13667","article-title":"Novel aspects of the phosphorylation and structure of pathological tau: implications for tauopathy biomarkers","volume":"14","author":"Kimura","year":"2024","journal-title":"FEBS Open Bio"},{"key":"B134","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate alzheimer's disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"B135","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40263-017-0434-z","article-title":"Elucidating the A\u03b242 anti-aggregation mechanism of action of tramiprosate in alzheimer's disease: integrating molecular analytical methods, pharmacokinetic and clinical data","volume":"31","author":"Kocis","year":"2017","journal-title":"CNS Drugs"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jalz.2018.05.017","article-title":"N-methyl-D-aspartate receptor-mediated calcium influx connects amyloid-\u03b2 oligomers to ectopic neuronal cell cycle reentry in alzheimer's disease","volume":"14","author":"Kodis","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.52711\/0974-360X.2021.00333","article-title":"Chronic treatment with escitalopram reversed Scopolamine-induced memory impairment by enhancing cholinergic activity in wistar albino rats","volume":"14","author":"Krishna","year":"2021","journal-title":"Res. J. Pharm. Technol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"102599","DOI":"10.1016\/j.arr.2024.102599","article-title":"An overview of the genes and biomarkers in Alzheimer\u2019s disease","volume":"104","author":"Krishnamurthy","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3390\/ph18081117","article-title":"New approaches to the treatment of alzheimer's disease","volume":"18","author":"Kruk-Slomka","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B140","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3390\/biom13030453","article-title":"The amyloid Cascade hypothesis in alzheimer's disease: should we change our thinking?","volume":"13","author":"Kurkinen","year":"2023","journal-title":"Biomolecules"},{"key":"B141","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes","volume":"9","author":"Kwon","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/npp.2013.70","article-title":"Blockade of tau hyperphosphorylation and A\u03b21\u201342 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and \u03c31 receptor agonist, in a nontransgenic mouse model of alzheimer\u2019s disease","volume":"38","author":"Lahmy","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"B143","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3389\/fncel.2014.00463","article-title":"Mitochondrial protection by the mixed muscarinic\/\u03c31 ligand ANAVEX2-73, a tetrahydrofuran derivative, in A\u03b225\u201335 peptide-injected mice, a nontransgenic Alzheimer\u2019s disease model","volume":"8","author":"Lahmy","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"B144","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.neuropharm.2014.01.011","article-title":"Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates A\u03b21-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice","volume":"79","author":"Lai","year":"2014","journal-title":"Neuropharmacology"},{"key":"B145","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.trci.2017.04.003","article-title":"Multiple-dose ponezumab for mild-to-moderate alzheimer's disease: safety and efficacy","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B146","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","article-title":"Safety, efficacy, and biomarker findings of PBT2 in targeting A\u03b2 as a modifying therapy for alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial","volume":"7","author":"Lannfelt","year":"2008","journal-title":"Lancet Neurology"},{"key":"B147","doi-asserted-by":"publisher","first-page":"e1002270","DOI":"10.1371\/journal.pmed.1002270","article-title":"APP, PSEN1, and PSEN2 mutations in early-onset alzheimer disease: a genetic screening study of familial and sporadic cases","volume":"14","author":"Lanoisel\u00e9e","year":"2017","journal-title":"PLoS Med."},{"key":"B148","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/011570159x379926250801062557","article-title":"Protein kinases in alzheimer's disease: pioneering insights into pathogenesis and therapeutic breakthroughs","volume":"24","author":"Lari","year":"2025","journal-title":"Curr. Neuropharmacol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fnmol.2017.00221","article-title":"Physiological concentrations of amyloid beta regulate recycling of synaptic vesicles via Alpha7 acetylcholine receptor and CDK5\/Calcineurin signaling","volume":"10","author":"Lazarevic","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/ggi.13488","article-title":"Dementia and alzheimer's disease risks in patients with autoimmune disorders","volume":"18","author":"Li","year":"2018","journal-title":"Geriatr. Gerontol. Int."},{"key":"B151","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1172\/jci96429","article-title":"Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation","volume":"128","author":"Liao","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B152","doi-asserted-by":"publisher","first-page":"6871089","DOI":"10.1155\/2017\/6871089","article-title":"The role of neural plasticity in depression: from hippocampus to prefrontal cortex","volume":"2017","author":"Liu","year":"2017","journal-title":"Neural Plast."},{"key":"B153","doi-asserted-by":"publisher","first-page":"e2527","DOI":"10.1002\/brb3.2527","article-title":"Effect of metal ions on alzheimer's disease","volume":"12","author":"Liu","year":"2022","journal-title":"Brain Behav."},{"key":"B154","doi-asserted-by":"publisher","first-page":"e22942","DOI":"10.1002\/jbt.22942","article-title":"Imbalanced GSH\/ROS and sequential cell death","volume":"36","author":"Liu","year":"2022","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/s41582-025-01154-y","article-title":"Towards pharmacological prevention of alzheimer disease","volume":"21","author":"Llibre-Guerra","year":"2025","journal-title":"Nat. Rev. Neurol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3390\/brainsci13121641","article-title":"The novel antipsychotic lumateperone (Iti-007) in the treatment of schizophrenia: a systematic review","volume":"13","author":"Longo","year":"2023","journal-title":"Brain Sci."},{"key":"B157","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/jad-141959","article-title":"A phase II trial of tideglusib in alzheimer's disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"B158","doi-asserted-by":"publisher","first-page":"103097","DOI":"10.1016\/j.arr.2026.103097","article-title":"Tau phosphorylation homeostasis: mechanisms, targets, and therapeutic implications in alzheimer's disease","volume":"118","author":"Lu","year":"2026","journal-title":"Ageing Res. Rev."},{"key":"B159","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/wad.0000000000000677","article-title":"Protocol for a randomized phase II\/III double-blind placebo-controlled trial to evaluate the safety and efficacy of extended-release metformin in amnestic mild cognitive impairment: Metformin in alzheimer dementia prevention (MAP)","volume":"39","author":"Luchsinger","year":"2025","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"B160","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/B978-0-12-394816-8.00006-4","article-title":"Scyllo-inositol, preclinical, and clinical data for Alzheimer\u2019s disease","volume":"64","author":"Ma","year":"2012","journal-title":"Adv. Pharmacology"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3390\/molecules27041210","article-title":"Amyloidosis in alzheimer's disease: Pathogeny, etiology, and related therapeutic directions","volume":"27","author":"Ma","year":"2022","journal-title":"Molecules"},{"key":"B162","doi-asserted-by":"publisher","first-page":"100016","DOI":"10.1016\/j.tjpad.2024.100016","article-title":"Blarcamesine for the treatment of early alzheimer's disease: results from the ANAVEX2-73-AD-004 phase IIB\/III trial","volume":"12","author":"Macfarlane","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B163","doi-asserted-by":"publisher","first-page":"850","DOI":"10.2174\/0115680266282492240220101049","article-title":"The unveiling of therapeutic targets for alzheimer's disease: an integrative review","volume":"24","author":"Madar","year":"2024","journal-title":"Curr. Top. Med. Chem."},{"key":"B164","doi-asserted-by":"publisher","first-page":"24932","DOI":"10.52965\/001c.24932","article-title":"Lumateperone tosylate, A selective and concurrent modulator of serotonin, dopamine, and glutamate, in the treatment of schizophrenia","volume":"9","author":"Maini","year":"2021","journal-title":"Health Psychol. Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/d41586-018-05719-4","article-title":"The amyloid hypothesis on trial","volume":"559","author":"Makin","year":"2018","journal-title":"Nature"},{"key":"B166","doi-asserted-by":"publisher","first-page":"113209","DOI":"10.1016\/j.ejmech.2021.113209","article-title":"Amyloid-\u03b2 and tau aggregation dual-inhibitors: a synthetic and structure-activity relationship focused review","volume":"214","author":"Malafaia","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B167","doi-asserted-by":"publisher","first-page":"e01347","DOI":"10.1002\/adts.202501347","article-title":"A predictive ML-QSAR approach for targeting GSK-3\u03b2 in alzheimer's disease","volume":"9","author":"Maliyakkal","year":"2026","journal-title":"Adv. Theory Simulations"},{"key":"B168","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3233\/jad-160544","article-title":"A phase IIa randomized control trial of VEL015 (sodium selenate) in mild-moderate alzheimer's disease","volume":"54","author":"Malpas","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"B169","doi-asserted-by":"publisher","first-page":"177529","DOI":"10.1016\/j.ejphar.2025.177529","article-title":"Oligonucleotide-based therapeutics for neurodegenerative disorders: focus on antisense oligonucleotides","volume":"998","author":"Mansour","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"105178","DOI":"10.1016\/j.neuint.2021.105178","article-title":"Inhibition of mitochondrial pyruvate carrier 1 by lapatinib ditosylate mitigates alzheimer's-like disease in D-galactose\/ovariectomized rats","volume":"150","author":"Mansour","year":"2021","journal-title":"Neurochem. Int."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.4103\/1673-5374.332132","article-title":"Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in alzheimer's disease","volume":"17","author":"Mansour","year":"2022","journal-title":"Neural Regen. Res."},{"key":"B172","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fneur.2020.00614","article-title":"A review on tramiprosate (homotaurine) in alzheimer's disease and other neurocognitive disorders","volume":"11","author":"Manzano","year":"2020","journal-title":"Front. Neurol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nature02621","article-title":"Pathways towards and away from alzheimer's disease","volume":"430","author":"Mattson","year":"2004","journal-title":"Nature"},{"key":"B174","doi-asserted-by":"publisher","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","article-title":"A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in alzheimer's disease","volume":"6","author":"Mattsson-Carlgren","year":"2020","journal-title":"Sci. Adv."},{"key":"B175","doi-asserted-by":"publisher","first-page":"Cd003154","DOI":"10.1002\/14651858.CD003154.pub6","article-title":"Memantine for dementia","volume":"3","author":"McShane","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B176","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrd2314","article-title":"Therapies for alzheimer's disease","volume":"6","author":"Melnikova","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"B177","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1586\/14737175.1.1.61","article-title":"Use of acetylcholinesterase inhibitors in alzheimer's disease","volume":"1","author":"Moghul","year":"2001","journal-title":"Expert Rev. Neurother."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.2174\/1389450122666210515161312","article-title":"Role of \u03b3-Secretase inhibitors for the treatment of diverse disease conditions through inhibition of notch signaling pathway","volume":"22","author":"Mondal","year":"2021","journal-title":"Curr. Drug Targets"},{"key":"B179","doi-asserted-by":"publisher","first-page":"115522","DOI":"10.1016\/j.bcp.2023.115522","article-title":"Alzheimer's disease: insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs","volume":"211","author":"Monteiro","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"e1391","DOI":"10.1212\/wnl.0000000000207663","article-title":"Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate alzheimer disease: Lauriet","volume":"101","author":"Monteiro","year":"2023","journal-title":"Neurology"},{"key":"B181","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000348347","article-title":"A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment","volume":"35","author":"Morimoto","year":"2013","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"B182","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1007\/s10787-026-02151-3","article-title":"Bridging the gaps in alzheimer\u2019s disease: a comprehensive review of current and emerging therapies","volume":"34","author":"Mostafa","year":"2026","journal-title":"Inflammopharmacology"},{"key":"B183","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/461895a","article-title":"Alzheimer's disease","volume":"461","author":"Mucke","year":"2009","journal-title":"Nature"},{"key":"B184","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPT(Rx) in mild alzheimer's disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat. Med."},{"key":"B185","doi-asserted-by":"publisher","first-page":"107962","DOI":"10.1016\/j.celrep.2020.107962","article-title":"In vivo chimeric alzheimer's disease modeling of apolipoprotein E4 toxicity in human neurons","volume":"32","author":"Najm","year":"2020","journal-title":"Cell. Rep."},{"key":"B186","doi-asserted-by":"publisher","first-page":"43","DOI":"10.14336\/ad.2023.0608","article-title":"Alzheimer's disease puzzle: delving into pathogenesis hypotheses","volume":"15","author":"Nasb","year":"2024","journal-title":"Aging Dis."},{"key":"B187","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019","volume":"7","author":"Nichols","year":"2022","journal-title":"Lancet Public Health"},{"key":"B188","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/s1474-4422(16)30331-3","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Novak","year":"2017","journal-title":"Lancet Neurol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13195-018-0436-1","article-title":"FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in alzheimer's disease","volume":"10","author":"Novak","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"B190","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13195-020-00614-5","article-title":"Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study","volume":"12","author":"Novak","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"B191","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/1567205011310010014","article-title":"Microdose lithium treatment stabilized cognitive impairment in patients with alzheimer's disease","volume":"10","author":"Nunes","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"B192","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/s1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuint.2017.08.010","article-title":"Alzheimer's disease as oligomeropathy","volume":"119","author":"Ono","year":"2018","journal-title":"Neurochem. Int."},{"key":"B194","doi-asserted-by":"publisher","first-page":"14794","DOI":"10.3390\/ijms241914794","article-title":"Amyloid precursor protein and alzheimer's disease","volume":"24","author":"Orobets","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70050","article-title":"The common Alzheimer's disease research ontology (CADRO) for biomarker categorization","volume":"11","author":"Osse","year":"2025","journal-title":"Alzheimers and Dementia-Translational Res. and Clin. Interventions"},{"key":"B196","doi-asserted-by":"publisher","first-page":"e70217","DOI":"10.1002\/trc2.70217","article-title":"Biomarkers in alzheimer's disease clinical trials: 2025","volume":"12","author":"Osse","year":"2026","journal-title":"Alzheimers and Dementia-Translational Res. and Clin. Interventions"},{"key":"B197","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early alzheimer disease: two phase 3 randomized placebo-controlled trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol."},{"key":"B198","doi-asserted-by":"publisher","first-page":"112940","DOI":"10.1016\/j.intimp.2024.112940","article-title":"Unveiling the role of astrogliosis in alzheimer's disease pathology: insights into mechanisms and therapeutic approaches","volume":"141","author":"Paidlewar","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"102336","DOI":"10.1016\/j.xcrp.2024.102336","article-title":"De novo design of a mechano-pharmaceutical screening platform against formation of individual beta-amyloid oligomers","volume":"5","author":"Pandey","year":"2024","journal-title":"Cell. Rep. Phys. Sci."},{"key":"B200","doi-asserted-by":"publisher","first-page":"9627699","DOI":"10.1155\/bn\/9627699","article-title":"Alzheimer's disease: the current and emerging treatment approaches","volume":"2025","author":"Pang","year":"2025","journal-title":"Behav. Neurol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"e2217864120","DOI":"10.1073\/pnas.2217864120","article-title":"A Cdk5-derived peptide inhibits Cdk5\/p25 activity and improves neurodegenerative phenotypes","volume":"120","author":"Pao","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B202","doi-asserted-by":"publisher","first-page":"105322","DOI":"10.1016\/j.ebiom.2024.105322","article-title":"Insights into the use of biomarkers in clinical trials in alzheimer's disease","volume":"108","author":"Pascoal","year":"2024","journal-title":"EBioMedicine"},{"key":"B203","doi-asserted-by":"publisher","first-page":"102698","DOI":"10.1016\/j.arr.2025.102698","article-title":"Repurposing drugs: promising therapeutic approach against alzheimer's disease","volume":"106","author":"Pattanaik","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"B204","doi-asserted-by":"publisher","first-page":"1206572","DOI":"10.3389\/fnagi.2023.1206572","article-title":"Current and future therapeutic strategies for alzheimer's disease: an overview of drug development bottlenecks","volume":"15","author":"Peng","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"B205","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3233\/jad-150896","article-title":"Differential membrane toxicity of Amyloid-\u03b2 fragments by pore forming mechanisms","volume":"51","author":"Peters","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"B206","volume-title":"Axon Announces Positive Results from Phase II ADAMANT Trial for AADvac1 in Alzheimer\u2019s Disease","author":"Phase","year":"2019"},{"key":"B207","doi-asserted-by":"publisher","first-page":"173290","DOI":"10.1016\/j.ejphar.2020.173290","article-title":"Neuroprotective potential of antihyperglycemic drug metformin in streptozocin-induced rat model of sporadic alzheimer's disease","volume":"881","author":"Pilipenko","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/iub.1262","article-title":"Selenium and selenoprotein function in brain disorders","volume":"66","author":"Pillai","year":"2014","journal-title":"IUBMB Life"},{"key":"B209","doi-asserted-by":"publisher","first-page":"105010","DOI":"10.1016\/j.nbd.2020.105010","article-title":"Passive immunotherapies targeting A\u03b2 and tau in alzheimer's disease","volume":"144","author":"Plotkin","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"B210","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/bcpt.14055","article-title":"Drugs targeting APOE4 that regulate beta\u2010amyloid aggregation in the brain: therapeutic potential for alzheimer's disease","volume":"135","author":"Poblano","year":"2024","journal-title":"Basic and Clin. Pharmacol. and Toxicol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13195-021-00843-2","article-title":"A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild alzheimer's disease","volume":"13","author":"Prins","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"B212","doi-asserted-by":"publisher","first-page":"105773","DOI":"10.1016\/j.neuint.2024.105773","article-title":"Ferroptosis: a new strategy for targeting alzheimer's disease","volume":"178","author":"Qiang","year":"2024","journal-title":"Neurochem. Int."},{"key":"B213","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.trci.2018.10.007","article-title":"A randomized, single ascending dose study of intravenous BIIB092 in healthy participants","volume":"4","author":"Qureshi","year":"2018","journal-title":"Alzheimer's and Dementia Transl. Res. and Clin. Interventions"},{"key":"B214","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/psyg.12944","article-title":"Aducanumab for the treatment of alzheimer's disease: a systematic review","volume":"23","author":"Rahman","year":"2023","journal-title":"Psychogeriatrics"},{"key":"B215","doi-asserted-by":"publisher","first-page":"119857","DOI":"10.1016\/j.cca.2024.119857","article-title":"Biomarkers in alzheimer's disease","volume":"562","author":"Rajendran","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"B216","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41591-025-03569-y","article-title":"Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial","volume":"31","author":"Rajji","year":"2025","journal-title":"Nat. Med."},{"key":"B217","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2174\/1570159x18666200807130637","article-title":"Neurodegenerative pathways in alzheimer's disease: a review","volume":"19","author":"Ramachandran","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"B218","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3233\/jad-170351","article-title":"Curcumin inhibits tau aggregation and disintegrates preformed tau filaments in vitro","volume":"60","author":"Rane","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"B219","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00210-015-1148-8","article-title":"Protective effect of a calcium channel blocker \u201cdiltiazem\u201d on aluminum chloride-induced dementia in mice","volume":"388","author":"Rani","year":"2015","journal-title":"Naunyn-Schmiedeberg's Archives Pharmacol."},{"key":"B220","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/life13010001","article-title":"The allosteric antagonist of the Sigma-2 receptors-elayta (CT1812) as a therapeutic candidate for mild to moderate alzheimer's disease: a scoping systematic review","volume":"13","author":"Rasheed","year":"2022","journal-title":"Life (Basel)"},{"key":"B221","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/wad.0000000000000680","article-title":"An anti-tau therapeutic antibody etalanetug (E2814): a phase 1, first-in-human (FIH) study of single and multiple ascending doses in healthy subjects","volume":"39","author":"Rawal","year":"2025","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"B222","doi-asserted-by":"publisher","first-page":"104005","DOI":"10.1016\/j.mcn.2025.104005","article-title":"GSK-3\u03b2 dysregulation in aging: implications for tau pathology and alzheimer's disease progression","volume":"133","author":"Rekha","year":"2025","journal-title":"Mol. Cell. Neurosci."},{"key":"B223","doi-asserted-by":"publisher","first-page":"8807","DOI":"10.1523\/JNEUROSCI.1521-05.2005","article-title":"Green tea Epigallocatechin-3-Gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in alzheimer transgenic mice","volume":"25","author":"Rezai-Zadeh","year":"2005","journal-title":"J. Neurosci."},{"key":"B224","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.brainres.2008.02.107","article-title":"Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in alzheimer transgenic mice","volume":"1214","author":"Rezai-Zadeh","year":"2008","journal-title":"Brain Res."},{"key":"B225","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3390\/life11080767","article-title":"Oxidative stress and the neurovascular unit","volume":"11","author":"Rinaldi","year":"2021","journal-title":"Life"},{"key":"B226","doi-asserted-by":"publisher","first-page":"1198299","DOI":"10.3389\/fnmol.2023.1198299","article-title":"Deleterious and protective effects of epothilone-D alone and in the context of amyloid \u03b2- and tau-induced alterations","volume":"16","author":"Robles-G\u00f3mez","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"B227","volume-title":"Roche to Discontinue Phase III CREAD 1 and 2 Clinical Studies of Crenezumab in Early Alzheimer's disease (Ad)-Other Company Programmes in AD Continue","author":"Roche","year":"2019"},{"key":"B228","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3233\/jad-151208","article-title":"Selenoprotein S reduces endoplasmic reticulum stress-induced phosphorylation of tau: potential role in selenate mitigation of tau pathology","volume":"55","author":"Rueli","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"B229","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fmed.2024.1474043","article-title":"Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges","volume":"11","author":"Safiri","year":"2024","journal-title":"Front. Med."},{"key":"B230","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/1061186x.2024.2365263","article-title":"Unlocking hope: GSK-3 inhibitors and wnt pathway activation in Alzheimer's therapy","volume":"32","author":"Sai","year":"2024","journal-title":"J. Drug Target"},{"key":"B231","doi-asserted-by":"publisher","first-page":"115697","DOI":"10.1016\/j.taap.2021.115697","article-title":"Tadalafil and bergapten mitigate streptozotocin-induced sporadic alzheimer's disease in mice via modulating neuroinflammation, PI3K\/Akt, Wnt\/\u03b2-catenin, AMPK\/mTOR signaling pathways","volume":"429","author":"Salem","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B232","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","article-title":"A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate alzheimer disease","volume":"77","author":"Salloway","year":"2011","journal-title":"Neurology"},{"key":"B233","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate alzheimer's disease (BLAZE)","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"B234","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat. Med."},{"key":"B235","doi-asserted-by":"publisher","first-page":"CD005380","DOI":"10.1002\/14651858.CD005380.pub5","article-title":"Metal protein attenuating compounds for the treatment of Alzheimer's dementia","author":"Sampson","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B236","doi-asserted-by":"publisher","first-page":"108104","DOI":"10.1016\/j.neuropharm.2020.108104","article-title":"Tau immunotherapies: lessons learned, current status and future considerations","volume":"175","author":"Sandusky-Beltran","year":"2020","journal-title":"Neuropharmacology"},{"key":"B237","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.3390\/molecules26102843","article-title":"Modulation of \u03b3-Secretase activity by a carborane-based flurbiprofen analogue","volume":"26","author":"Saretz","year":"2021","journal-title":"Molecules"},{"key":"B238","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1021\/acs.chemrev.8b00138","article-title":"Development of multifunctional molecules as potential therapeutic candidates for alzheimer\u2019s disease, parkinson\u2019s disease, and amyotrophic lateral sclerosis in the last decade","volume":"119","author":"Savelieff","year":"2019","journal-title":"Chem. Rev."},{"key":"B239","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13195-018-0431-6","article-title":"Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study","volume":"10","author":"Scheltens","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"B240","doi-asserted-by":"publisher","first-page":"100630","DOI":"10.1016\/j.lanhl.2024.07.013","article-title":"Challenges in the practical implementation of blood biomarkers for alzheimer's disease","volume":"5","author":"Sch\u00f6ll","year":"2024","journal-title":"Lancet Healthy Longev."},{"key":"B241","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1039\/d4md00729h","article-title":"Peptide-based amyloid-beta aggregation inhibitors","volume":"16","author":"Sehra","year":"2025","journal-title":"RSC Med. Chem."},{"key":"B242","doi-asserted-by":"publisher","first-page":"9917","DOI":"10.1523\/jneurosci.0621-17.2017","article-title":"Inhibition of p25\/Cdk5 attenuates tauopathy in mouse and iPSC models of frontotemporal dementia","volume":"37","author":"Seo","year":"2017","journal-title":"J. Neurosci."},{"key":"B243","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"B244","doi-asserted-by":"publisher","first-page":"577","DOI":"10.4103\/nrr.Nrr-d-24-00846","article-title":"Recent advances in immunotherapy targeting amyloid-beta and tauopathies in alzheimer's disease","volume":"21","author":"Sha","year":"2026","journal-title":"Neural Regen. Res."},{"key":"B245","doi-asserted-by":"publisher","first-page":"11326","DOI":"10.3390\/ijms241411326","article-title":"Screening for novel inhibitors of amyloid beta aggregation and toxicity as potential drugs for alzheimer's disease","volume":"24","author":"Sharari","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B246","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11011-025-01587-w","article-title":"Ferroptosis and Alzheimer\u2019s: unveiling new avenues for the treatment and prevention","volume":"40","author":"Sharma","year":"2025","journal-title":"Metab. Brain Dis."},{"key":"B247","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1093\/cercor\/bhv032","article-title":"Cdk5 is a new rapid synaptic homeostasis regulator capable of initiating the early alzheimer-like pathology","volume":"26","author":"Sheng","year":"2016","journal-title":"Cereb. Cortex"},{"key":"B248","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","article-title":"ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy","volume":"549","author":"Shi","year":"2017","journal-title":"Nature"},{"key":"B249","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","article-title":"TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer\u2019s disease","volume":"3","author":"Shulman","year":"2023","journal-title":"Nat. Aging"},{"key":"B250","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"Jama"},{"key":"B251","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","article-title":"Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management","volume":"367","author":"Singh","year":"2024","journal-title":"J. Control Release"},{"key":"B252","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jagp.2017.10.010","article-title":"Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: a double-blind, placebo-controlled 18-Month trial","volume":"26","author":"Small","year":"2018","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"B253","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","article-title":"Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission","volume":"232","author":"Snyder","year":"2015","journal-title":"Psychopharmacology"},{"key":"B254","doi-asserted-by":"publisher","first-page":"590896","DOI":"10.3389\/fnmol.2020.590896","article-title":"New insights into drug discovery targeting tau protein","volume":"13","author":"Soeda","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"B255","doi-asserted-by":"publisher","first-page":"105940","DOI":"10.1016\/j.ebiom.2025.105940","article-title":"Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early alzheimer's disease: a phase 1b\/2a, multicentre, double-blind, randomised, placebo-controlled study","volume":"120","author":"Sol","year":"2025","journal-title":"Ebiomedicine"},{"key":"B256","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40035-022-00292-3","article-title":"Immunotherapy for alzheimer's disease: targeting \u03b2-amyloid and beyond","volume":"11","author":"Song","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"B257","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.freeradbiomed.2017.08.006","article-title":"NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: what is the evidence?","volume":"112","author":"Sorce","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"B258","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00210-017-1357-4","article-title":"Protective effect of valproic acid in streptozotocin-induced sporadic alzheimer's disease mouse model: possible involvement of the cholinergic system","volume":"390","author":"Sorial","year":"2017","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B259","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/jamaneurol.2020.4857","article-title":"Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical alzheimer disease: a truncated randomized phase 2b\/3 clinical trial","volume":"78","author":"Sperling","year":"2021","journal-title":"JAMA Neurol."},{"key":"B260","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/brain\/awaa089","article-title":"Relationship between cortical iron and tau aggregation in alzheimer's disease","volume":"143","author":"Spotorno","year":"2020","journal-title":"Brain"},{"key":"B261","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/ph18050659","article-title":"A review of the clinical progress of CT1812, a novel sigma-2 receptor antagonist for the treatment of Alzheimer\u2019s disease","volume":"18","author":"Steinfield","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012921","article-title":"Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected","volume":"12","author":"Su\u00e1rez-Calvet","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"B263","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1038\/mtna.2014.30","article-title":"Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies","volume":"3","author":"Sud","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B264","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"B265","first-page":"1040","article-title":"scyllo-Inositol, a therapeutic agent for Alzheimer\u2019s disease","volume":"2","author":"Tanaka","year":"2015","journal-title":"Austin J. Clin. Neurol."},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19123824","article-title":"The role of NADPH oxidases and oxidative stress in neurodegenerative disorders","volume":"19","author":"Tarafdar","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B267","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2022.01.016","article-title":"Challenges and hopes for alzheimer's disease","volume":"27","author":"Tatulian","year":"2022","journal-title":"Drug Discov. Today"},{"key":"B268","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of semorinemab in individuals with prodromal to mild alzheimer disease: a randomized clinical trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol."},{"key":"B269","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","article-title":"Neuroinflammation in alzheimer's disease: current progress in molecular signaling and therapeutics","volume":"46","author":"Thakur","year":"2023","journal-title":"Inflammation"},{"key":"B270","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejmech.2014.01.020","article-title":"Synthesis, biological evaluation and molecular modeling study of novel tacrine\u2013carbazole hybrids as potential multifunctional agents for the treatment of alzheimer's disease","volume":"75","author":"Thiratmatrakul","year":"2014","journal-title":"Eur. Journal Medicinal Chemistry"},{"key":"B271","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.euroneuro.2022.06.009","article-title":"Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: a dopamine D(1) receptor dependent mechanism","volume":"62","author":"Titulaer","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B272","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/jgs.15069","article-title":"Comparative effectiveness and safety of cognitive enhancers for treating alzheimer's disease: systematic review and network metaanalysis","volume":"66","author":"Tricco","year":"2018","journal-title":"J. Am. Geriatr. Soc."},{"key":"B273","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","article-title":"Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial","volume":"77","author":"Tsai","year":"2020","journal-title":"JAMA Neurol."},{"key":"B274","doi-asserted-by":"publisher","first-page":"106479","DOI":"10.1016\/j.intimp.2020.106479","article-title":"Pharmacological approaches to mitigate neuroinflammation in Alzheimer\u2019s disease","volume":"84","author":"Uddin","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"B275","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/antiox12071460","article-title":"Alzheimer\u2019s disease and green tea: Epigallocatechin-3-Gallate as a modulator of inflammation and oxidative stress","volume":"12","author":"Valverde-Salazar","year":"2023","journal-title":"Antioxidants"},{"key":"B276","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B277","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3233\/jad-210268","article-title":"NLRP3 inflammasome: a starring role in Amyloid-\u03b2- and tau-driven pathological events in alzheimer's disease","volume":"83","author":"Van Zeller","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"B278","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate alzheimer's disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"B279","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13024-024-00725-9","article-title":"Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in alzheimer's disease","volume":"19","author":"Vandermeulen","year":"2024","journal-title":"Mol. Neurodegener."},{"key":"B280","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3389\/fncel.2018.00226","article-title":"Repositioning microtubule stabilizing drugs for brain disorders","volume":"12","author":"Varidaki","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"B281","doi-asserted-by":"publisher","first-page":"173554","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer's disease: recent treatment strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"B282","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2174\/156720511795256053","article-title":"EHT0202 in alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study","volume":"8","author":"Vellas","year":"2011","journal-title":"Curr. Alzheimer Res."},{"key":"B283","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/13543784.2023.2178414","article-title":"Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of alzheimer disease","volume":"32","author":"Vitek","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B284","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/vaccines12090973","article-title":"Active immunotherapy for the prevention of alzheimer's and parkinson's disease","volume":"12","author":"Vroom","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B285","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1042\/bst0350416","article-title":"The APP family of proteins: similarities and differences","volume":"35","author":"Walsh","year":"2007","journal-title":"Biochem. Soc. Trans."},{"key":"B286","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3233\/jad-160763","article-title":"Role of glutamate and NMDA receptors in alzheimer's disease","volume":"57","author":"Wang","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"B287","doi-asserted-by":"publisher","first-page":"6697","DOI":"10.1096\/fj.201801751R","article-title":"Ca(2+) homeostasis dysregulation in alzheimer's disease: a focus on plasma membrane and cell organelles","volume":"33","author":"Wang","year":"2019","journal-title":"Faseb J."},{"key":"B288","doi-asserted-by":"publisher","first-page":"e2698","DOI":"10.1371\/journal.pone.0002698","article-title":"Age-specific epigenetic drift in late-onset alzheimer's disease","volume":"3","author":"Wang","year":"2008","journal-title":"PLoS One"},{"key":"B289","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nrneurol.2017.111","article-title":"A systemic view of alzheimer disease - insights from amyloid-\u03b2 metabolism beyond the brain","volume":"13","author":"Wang","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"B290","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.trci.2017.03.005","article-title":"UB-311, a novel UBITh(\u00ae) amyloid \u03b2 peptide vaccine for mild alzheimer's disease","volume":"3","author":"Wang","year":"2017","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B291","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1021\/acschemneuro.3c00343","article-title":"Ferroptosis, pyroptosis, and cuproptosis in alzheimer's disease","volume":"14","author":"Wang","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"B292","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/alz.12164","article-title":"Cognitive outcomes in trials of two BACE inhibitors in alzheimer's disease","volume":"16","author":"Wessels","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B293","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/s1474-4422(12)70140-0","article-title":"Safety, tolerability, and antibody response of active A\u03b2 immunotherapy with CAD106 in patients with alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study","volume":"11","author":"Winblad","year":"2012","journal-title":"Lancet Neurol."},{"key":"B294","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3233\/jad-142874","article-title":"Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate alzheimer's disease","volume":"44","author":"Wischik","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"B295","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.3390\/ijms24054367","article-title":"Aducanumab-hope or disappointment for alzheimer's disease","volume":"24","author":"Wojtunik-Kulesza","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B296","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.bbrc.2009.10.093","article-title":"Alzheimer\u2019s disease and notch signaling","volume":"390","author":"Woo","year":"2009","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B297","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1096\/fj.201902230RR","article-title":"A\u03b2 monomer induces phosphorylation of tau at Ser-214 through \u03b22AR-PKA-JNK signaling pathway","volume":"34","author":"Wu","year":"2020","journal-title":"Faseb J."},{"key":"B298","doi-asserted-by":"publisher","first-page":"100112","DOI":"10.1016\/j.medp.2025.100112","article-title":"Advancement of disease-modifying therapy of Alzheimer\u2019s disease: from the perspective of new revised criteria for diagnosis and staging of Alzheimer\u2019s disease","volume":"2","author":"Wu","year":"2025","journal-title":"Med. Plus"},{"key":"B299","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.3390\/ijms26083905","article-title":"Recent advances in drug development for alzheimer's disease: a comprehensive review","volume":"26","author":"Xing","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B300","doi-asserted-by":"publisher","first-page":"eabd7522","DOI":"10.1126\/scitranslmed.abd7522","article-title":"APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function","volume":"13","author":"Xiong","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"B301","doi-asserted-by":"publisher","first-page":"10591","DOI":"10.1002\/slct.201902852","article-title":"The development of small molecule inhibitors of glutaminyl cyclase and isoglutaminyl cyclase for alzheimer's disease","volume":"4","author":"Xu","year":"2019","journal-title":"ChemistrySelect"},{"key":"B302","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1515\/revneuro-2022-0121","article-title":"Ferroptosis: a potential therapeutic target for Alzheimer\u2019s disease","volume":"34","author":"Yang","year":"2023","journal-title":"Rev. Neurosci."},{"key":"B303","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.2174\/0118715273258337230925040049","article-title":"Montelukast ameliorates scopolamine-induced alzheimer's disease: role on cholinergic neurotransmission, antioxidant defence system, neuroinflammation and expression of BDNF","volume":"23","author":"Yerraguravagari","year":"2024","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B304","doi-asserted-by":"publisher","first-page":"173612","DOI":"10.1016\/j.ejphar.2020.173612","article-title":"Neuroprotective effects of vildagliptin on drug induced alzheimer's disease in rats with metabolic syndrome: role of hippocampal klotho and AKT signaling pathways","volume":"889","author":"Yossef","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"B305","doi-asserted-by":"publisher","first-page":"8208","DOI":"10.3390\/ijms22158208","article-title":"Novel therapeutic approaches for alzheimer's disease: an updated review","volume":"22","author":"Yu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B306","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40035-023-00336-2","article-title":"Combined metabolic activators improve cognitive functions in alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial","volume":"12","author":"Yulug","year":"2023","journal-title":"Transl. Neurodegener."},{"key":"B307","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bbr.2013.05.017","article-title":"Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP\/PS1 transgenic mice","volume":"250","author":"Zhang","year":"2013","journal-title":"Behav. Brain Res."},{"key":"B308","doi-asserted-by":"publisher","first-page":"313","DOI":"10.14283\/jpad.2021.15","article-title":"The epidemiology of alzheimer's disease modifiable risk factors and prevention","volume":"8","author":"Zhang","year":"2021","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B309","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1177\/13872877251322196","article-title":"Synergistic associations of amyloid-\u03b2 and phosphorylated tau with tau aggregation and cognitive decline in alzheimer's disease","volume":"104","author":"Zhang","year":"2025","journal-title":"J. Alzheimers Dis."},{"key":"B310","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/procel\/pwae026","article-title":"Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy","volume":"16","author":"Zheng","year":"2025","journal-title":"Protein Cell."},{"key":"B311","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/cne.24616","article-title":"Fluoxetine delays the cognitive function decline and synaptic changes in a transgenic mouse model of early alzheimer's disease","volume":"527","author":"Zhou","year":"2019","journal-title":"J. Comp. Neurol."},{"key":"B312","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1126\/science.aay0198","article-title":"A vicious cycle of \u03b2 amyloid-dependent neuronal hyperactivation","volume":"365","author":"Zott","year":"2019","journal-title":"Science."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1819165\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:57:40Z","timestamp":1781675860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1819165\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":312,"alternative-id":["10.3389\/fphar.2026.1819165"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1819165","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1819165"}}